Cipla Sees Muted First Quarter Amid Distributor 'Churn' In India
Executive Summary
A significant shake-up of distributors in the Indian market impacted Cipla’s first-quarter earnings but the firm expects to bounce back. Biosimilars in emerging markets and opportunities in China are among the growth drivers it is banking on.
You may also be interested in...
Cipla And Alvotech Prime Emerging Markets Push With Adalimumab Deal
Cipla has firmed up a commercialization deal with Alvotech for the Icelandic developer’s high-concentration version of AbbVie’s Humira, continuing to use the licensing approach to expand its biosimilar franchise in emerging markets.
Cipla-Alvotech Prime Emerging Markets Push With Humira Biosimilar Deal
Cipla has firmed up a commercialization deal with Alvotech for the Icelandic developer’s high-concentration version of AbbVie’s Humira, continuing to use the licensing approach to expand its biosimilar franchise in emerging markets.
Cipla Docks Into China With Manufacturing Plans In Tow
More Indian companies are headed to China, with Cipla the latest to seal a joint venture there, though the firm has previous links with the country. Respiratory products will lead Cipla’s line-up in China, a market seen as a crucial cog in the firm’s future road map.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: